Salute e Benessere

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast…

Key Takeaways from the Interleukin-17 Inhibitors Market Report Key Takeaways from the Interleukin-17 Inhibitors Market Report Discover which indication is expected to grab the major interleukin-17 inhibitors market share @Interleukin-17 Inhibitors Market Report Interleukin-17 Inhibitors Market Dynamics The interleukin-17 inhibitors market has witnessed significant growth over the past decade, driven by theincreasing prevalence of chronic immune-mediated inflammatory...

KLEA HOLDING (ex VISIOMED GROUP) : Klea Holding accelerates its growth in the…

Number of tests performed up by +55% compared with +24% in 2024; Sales up +48% at constant exchange rates; Confirmation of development and performance plan. Paris, 21 July 2025 KLEA HOLDING (FR0013481835 - ALKLH), a group specialising in the acquisition, development and digitalisation of companies in various sectors, presents its unaudited sales…

CARBIOS enters the r-PET market for tire textile filaments

CARBIOS has signed a multi-year commercial agreement with Indorama Ventures, the world leader in polyester production. CARBIOS will supply recycled monomers that will be transformed into filaments by Indorama Ventures, intended for use in tire reinforcement for Michelin.This new commercial agreement highlights the interest of a new market—industrial fabrics—for high-quality r-PET derived from enzymatic recycling. Clermont-Ferrand (France), 21 July 2025 (17h45 CEST) – CARBIOS...

DMS GROUP: FURTHER INCREASE IN REVENUE +3% IN H1 2025

Further increase in a tense market environment and an unfavorable base effect A 2nd half of 2025 expected to see sustained growth, driven by the implementation of the Ukraine contract and the acceleration of commercial momentum Confirmation of Imaging 2027! plan €23.6 million Revenue 3% Rise Revenue vs 2024 July 21, 2025 – 5:45 pm – Diagnostic…

Breakup Blues Are Fuelling a Surge in Hair Transplant Travel, Says Clinic Prime

Clinic Prime , a UK-focused cosmetic medical provider based inIstanbul, reports a sharp uptick in bookings from recently single men. These patients aren't just chasing aesthetics — they're seeking closure, control, and confidence. "We've heard it dozens of times now: 'I just split up, and it's time to do something for me," said Sam, UK Representative for Clinic Prime. "It's a quiet form of self-reinvention." Why Post-Breakup Hair Transplants? Relationship endings often...

Organ Preservation Market worth $0.3 billion by 2030 with 6.8% CAGR |…

Browse in-depth TOC on "Organ Preservation Market" Browse in-depth TOC on "Organ Preservation Market" 300 - Tables100 - Figures400 - Pages By solution,the organ preservation market, by solution, is categorized into UW Solution, Custodial HTK, Perfadex, and other solutions (including EuroCollins and Celsior). The UW ( University of Wisconsin ) solution accounted for the largest market share in 2024. This solution is widely used for preserving and flushing organs such as...

Healthcare Consulting Services Market Worth $51.95 Billion by 2030 with 10.1%…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=41882774 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=41882774 Browse in-depth TOC on "Healthcare Consulting Services Market" 40 - Tables 50 - Figures 300 - Pages By service type,the healthcare consulting services market is segmented into IT & digital transformation consulting services; strategy consulting services; operation consulting services;...

LILYSILK Launches Fall 2025 Collection "Understated Strength", A Tribute to…

The collection is built around four core values: elegance, versatility, empowerment, and a connection to nature, expressed through clean lines, soft fabrics, and thoughtful details. "True strength doesn't always speak the loudest," said David Wang, CEO of LILYSILK. "This season, we wanted to create designs that feel calm yet confident, refined yet approachable." The collection is built around four core values: elegance, versatility, empowerment, and a connection to nature…

Veteran Global Health Leader, Dr. Rebecca Martin, Named President of Global…

WASHINGTON, July21, 2025(GLOBE NEWSWIRE) -- Renowned global health expert Rebecca Martin, PhD, recognized internationally for her leadership in developing and implementing immunization programs and strengthening health systems, joins the Sabin Vaccine Institute today as President of Global Immunization, assuming the reins of the nonprofit’s efforts in vaccination innovation and extending vaccine access.Martin most recently served as Vice President for Global Health at Emory...

Minaris Advanced Therapies Welcomes Orla Cloak as Chief Executive Officer

Iain Baird, Chairman of the Board, Minaris Advanced Therapies commented: "On behalf of the board, I am delighted to welcome Orla to Minaris Advanced Therapies. Her leadership will be instrumental to achieving our mission of supporting customers to successfully commercialize their innovative therapies." Iain Baird, Chairman of the Board, Minaris Advanced Therapies commented:"On behalf of the board, I am delighted to welcome Orla to Minaris Advanced Therapies. Her leadership will…

Endo to Report Second Quarter 2025 Financial Results on August 6, 2025

About EndoEndo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn. About EndoEndo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate...

Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch…

Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025 Gdańsk, Poland - July 21, 2025 - Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for cancer detection using a unique method of urine sample analysis, has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer – one of...

VEOCEL™'s Lyocell Fibers for Enhanced Cleaning Take Center Stage at World of…

Delivering Enhanced Cleaning Performance[3] Delivering Enhanced Cleaning Performance[3] VEOCEL™ Lyocell fibers for Enhanced Cleaning are engineered to improve wiping performance through stronger and denser fabrics and enhance the end-user experience. These fibers ensureeven liquid distribution, helping to reduce excess dripping and provide greater control during cleaning. Compared to fossil-based alternatives, each wipe canclean up to twice the surface area, offering...

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in…

FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease CAMBRIDGE, Mass., July21, 2025(GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD), today...

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced compelling immunologic findings from the treatment of a moderate Alzheimer's Disease (AD) patient with intranasal foralumab.Transcriptional analysis of white blood cells before and after foralumab therapy revealed profound immune modulatory effects. Significant...

BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on…

MAINZ, Germany, July 21, 2025 (GLOBE NEWSWIRE)-- BioNTech SE(Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2025 on Monday, August 4, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.To access the live conference call via telephone, please register...

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of…

– Alixorexton Was Generally Well Tolerated at All Doses Tested – – Alixorexton Was Generally Well Tolerated at All Doses Tested – – Detailed Results to Be Presented at Upcoming World Sleep Congress – – Data Support Advancement of Alixorexton to Phase 3 Development in Narcolepsy – DUBLIN , July 21, 2025 /PRNewswire/ -- Alkermes plc(Nasdaq: ALKS) today announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study...

Major shareholder announcement

Please read the full announcement in PDF.Attachments 2025_36_Major_Shareholders_AnnouncementNovozymes B 16 July 2025_FinalNovozymes B 01-07-2025_Final_HPS

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S…

The system is the first-ever to stimulate the heart muscle electrically via a small, leadless device—about the size of a grain of rice—that is implanted inside tissue of the left ventricle, the heart's primary pumping chamber. The device converts ultrasound energy into electrical pulses, restoring the heart's normal rhythm and pumping efficiency. The system is the first-ever to stimulate the heart muscle electrically via a small, leadless device—about the size of a grain of rice—that is...

Darolutamide receives EU approval in third indication for patients with advanced…

ORION CORPORATIONPRESS RELEASE21 JULY 2025 at 10:30 EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancerEuropean Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC).Approval is based on positive results from the pivotal Phase III ARANOTE trial.This broadened indication allows doctors to use...

EssilorLuxottica to acquire PUcore’s division dedicated to the development…

EssilorLuxottica to acquire PUcore’s division dedicated to the development, manufacturing and sale of ophthalmic lens materials The acquisition will enhance the Group’s R&D and production capabilities for the manufacturing of innovative high index, thinner and lighter ophthalmic lenses, and ensure long term sustainable sourcingParis, France (21 July 2025)– EssilorLuxottica announces today it has signed an agreement with the South Korean company PUcore for the acquisition of all...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on…

The pivotal phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every two weeksThe phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeksThe safety profile of astegolimab was consistent with previously reported data, with no new safety signals identifiedAnalysis of the ALIENTO and ARNASA data...

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Company announcement – No. 17 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V.Copenhagen, Denmark, July 18, 2025 –Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 18 July 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder:As of 17 July 2025, Van...

Disclosure of notification received from Alychlo

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 18 July 2025 – 6 PM CET Disclosure of notification received from AlychloFagron received a notification based on the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from Alychlo NV. Notification by Alychlo NVOn 14 July 2025, Fagron received a notification that the shareholding of Alychlo NV, crossed the disclosure threshold of 3% downwards as the result of the...

Altri Comunicati